Anuh Pharma Reports Q2 Revenue Of ₹1.85 Billion Vs ₹1.86 Billion YoY

Market snapshot: Anuh Pharma Ltd reported Q2 revenue of ₹1.85 billion compared to ₹1.86 billion in the corresponding period of the previous year. The top-line outcome reflects steady demand across its active pharmaceutical ingredients business with minimal year-on-year variation.

Data Snapshot

• Q2 revenue stood at ₹1.85 billion compared to ₹1.86 billion in the prior-year quarter.
• Year-on-year revenue performance showed a minor movement of approximately 0.54% down.

What's Changed

• Q2 revenue registered at ₹1.85 billion compared to ₹1.86 billion in the year-ago period.

Key Takeaways

• Top-line performance remained stable year-on-year with minimal top-line divergence.
• Revenue baseline highlights resilient off-take across active pharmaceutical ingredient categories.
• Consistent sales figures point to steady client retention and operational stability.

SAHI Perspective

Anuh Pharma's Q2 revenue figure of ₹1.85 billion demonstrates operational consistency in the active pharmaceutical ingredients market. With top-line figures virtually unchanged year-on-year, operational efficiency and cost management remain key factors for underlying profit margins.

Market Implications

The steady revenue output provides a neutral baseline for equity valuation, reassuring market participants of stable commercial volumes in bulk drugs.

Trading Signals

Market Bias: Neutral

Q2 revenue of ₹1.85 billion versus ₹1.86 billion YoY signals stable operational output without major directional disruption.

Overweight: Pharma APIs, Bulk Drugs

Trigger Factors:

• Full margin and net income disclosures in comprehensive filings
• Raw material pricing trends across bulk drug production inputs
• Export demand dynamics across active pharmaceutical product lines

Time Horizon: Near-term (0-3 months)

Industry Context

The active pharmaceutical ingredient market in India is maintaining stable output volumes while managing global input pricing and supply chain alignment.

Key Risks to Watch

• Volatile prices of raw material chemicals used in API manufacturing
• Regulatory compliance requirements across key foreign markets
• Price competition in generic drug active components

Recent Developments

Anuh Pharma convened its board meeting on October 30, 2026, to consider and approve financial results for the quarter ended September 30, 2026.

Closing Insight

Top-line stability establishes a predictable base for Anuh Pharma as it navigates operational efficiencies in active pharmaceutical manufacturing.

High Performance Trading with SAHI.